OCC 20.9% 66.5¢ orthocell limited

Further CelGro® nerve clinical trial data from all patients at 12 months, page-63

  1. 1,666 Posts.
    lightbulb Created with Sketch. 178
    I don’t think the US market is as easy to crack as
    some people hope. Aussie biotechs such as AVH,
    PNV, NXS have found the going tough, despite
    great best in market products and their share
    price has reacted accordingly.

    We can’t blame Covid for ever.

 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.